|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1650 Diagonal Road |
Address2 |
|
City | ALEXANDRIA |
State | VA |
Zip Code | 22314 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 1386-12
|
||||||||
|
6. House ID# 321810000
|
TYPE OF REPORT | 8. Year | 2018 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: James C. Denneny III, MD |
Date | 1/17/2019 3:21:21 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Federal "Truth in Advertising" legislation; in general.
H.R. 3928, the "Truth in Healthcare Marketing Act," all provisions.
Issues pertaining to scope of practice; in general.
Health care reform efforts; in general.
Repeal of the Affordable Care Act, in general.
Letter to the Food and Drug Administration regarding the forthcoming regulations relating to the over-the-counter sale of hearing aids.
Letter to the Food and Drug Administration regarding National Shortages of Lidocaine with Epinephrine, Lidocaine, and Other Local Anesthetics.
Coalition Letter to the Department of Health and Human Services Office of the Inspector General regarding information blocking by Electronic Health Record Vendors.
Letter to Congress regarding H.R. 5247/S. 204, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2018, all provisions.
H.Res.740, Expressing Support for the Designation of March 3, 2018, as World Hearing Day.
H.R. 6, the SUPPORT for Patients and Communities Act; Section 303.
S. 2852, the Pandemic All Hazards Preparedness and Advancing Innovation Act of 2018; provisions related to malpractice/tort reform and H.R. 1876.
Issues pertaining to Language Equality and Acquisition for Deaf Kids (LEAD-K) and parent choice; in general.
H.R. 1120, the "Alice Cogswell and Anne Sullivan Macy Act," all provisions.
Coalition letter to the National Coordinator for Health Information Technology at HHS regarding HHS-ONC-2018-022 - Request for Information Regarding the 21st Century Cures Act Electronic Health Reporting Program.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Joy |
Trimmer |
JD |
|
|
Amelia |
Suermann |
|
|
|
Maura |
Farrell |
|
|
|
Karl |
Melton |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R. 2276/S. 2575, the "Audiology Patient Choice Act," all provisions.
Medicare physician payment reform and implementation of the Medicare and CHIP Reauthorization Act of 2015, in general.
Medicare physician payment reform and implementation of the Medicare and CHIP Reauthorization Act of 2015 related to the cost domain of the Merit-based Incentive Payment System.
H.R. 1156, the "Patient Access to Higher Quality Health Care Act of 2017," all provisions.
H.R. 849/S. 260, the "Protecting Seniors' Access to Medicare Act of 2017," all provisions.
Comments outlining concern with the November 2017 Medicare Payment Advisory Commission (MedPAC) discussion titled, "Rebalancing the physician fee schedule towards primary care services."
Issues pertaining to scope of practice, in general.
Comments urging the Centers for Medicare and Medicaid Services (CMS) to reduce the 2018 Merit-based Incentive Payment System (MIPS) reporting period from a calendar year to a minimum of 90 consecutive days.
Comments on the Medicare Hospital IPPS FY 2019 Proposed Rule communicating concerns about the agencys plans to remove the Public Health and Clinical Data Exchange objective by 2022.
Comments urging leaders of the U.S. Senate Committee on Finance not to co-sponsor and oppose any efforts to advance the "Audiology Patient Choice Act" (S. 2575).
Comments to the Centers for Medicare and Medicaid Services (CMS) regarding Medicare's designation of CPT Code 31241 Nasal/sinus endoscopy, surgical; with ligation of sphenopalatine artery.
Coalition letter to leaders of the U.S. House Committees on Ways & Means and Energy & Commerce regarding the Medicare Appropriate Use Criteria (AUC) Program for Advanced Diagnostic Imaging.
Coalition letter to leaders of the U.S. Senate Committee on Finance regarding the Medicare Appropriate Use Criteria (AUC) Program for Advanced Diagnostic Imaging.
Coalition letter to U.S. House Committees on Ways & Means and Energy and Commerce and U.S. Senate Committee on Finance regarding payment cuts for clinical lab tests in the Medicare program.
Coalition letter to the CMS Administrator urging HHS to allow eligible clinicians utilizing a certified electronic health record to participate in a clinician-led qualified clinical data registry to qualify them as fully achieving all points from the MIPS program.
Coalition letter to the CMS Administrator regarding the Evaluation and Management coding and payment recommendations included in the CY19 Medicare Physician Fee Schedule Proposed Rule.
Coalition letter to U.S. House of Representatives requesting support of a letter to HHS Secretary Alex Azar regarding data information blocking guidelines as related to Qualified Clinical Data Registries.
Comments on the CY19 Medicare Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Payment System proposed rule communicating support for proposed changes to reduce site of service disparities, as well as removal of CPT 31241 (Nasal/sinus endoscopy, surgical; with ligation of sphenopalatine artery) from the Inpatient Only List.
Comments on the CY19 Medicare Physician Fee Schedule Proposed Rule regarding the proposed changes to documentation requirements, coding and payment for Evaluation and Management (E/M) services, application of the MPPR to E/M services, and the pricing and composition of balloon sinus surgery kits.
Coalition Letter to leaders of the U.S. Senate Committee on Finance and U.S. House Committees on Ways and Means and Energy and Commerce regarding cuts to clinical laboratory services implemented by the Protecting Access to Medicare Act (PAMA) of 2014.
Coalition letter to U.S. Senate Finance Committee and U.S. House Committees on Ways and Means and Energy and Commerce expressing concerns with CMS proposal to require Qualified Clinical Data Registry (QCDR) measure owners to enter into licensing agreements with CMS that would permit any other approved QCDR to submit data on the licensed measure for purposes of MIPS reporting.
Comments on the CY19 Medicare Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Payment System Final Rule regarding changes to reduce site of service disparities, as well as removal of CPT 31241 (Nasal/sinus endoscopy, surgical; with ligation of sphenopalatine artery) from the Inpatient Only List.
Comments on the CY 2019 Physician Fee Schedule Final Rule regarding the changes to documentation requirements, coding and payment for Evaluation and Management (E/M) services, application of the MPPR to E/M services, and the pricing and composition of balloon sinus surgery kits.
Coalition letter to CMS expressing several concerns with Qualified Clinical Data Registries and MIPS.
Coalition letter to CMS in response to an RFI regarding reporting requirements under the Open Payments Program for educational materials.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Medicare Payment Advisory Commission (MedPAC), Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Joy |
Trimmer |
JD |
|
|
Amelia |
Suermann |
|
|
|
Maura |
Farrell |
|
|
|
Karl |
Melton |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
H.R. 1892, the "Bipartisan Budget Act of 2018," provisions related to healthcare.
Opposition to H.R. 564 and any appropriations policy riders that would exempt some cigars, including flavored cigars, from regulation under the Family Smoking Prevention and Tobacco Control Act (TCA).
Coalition letter to members of U.S. House Committee on Appropriations regarding funding for universal newborn hearing screening programs, as authorized by H.R.1539/S.652 the "Early Hearing Detection and Intervention (EHDI) Act of 2017."
Coalition letter to U.S. Senate Appropriators to approve the authorized level of user fees for the FDA oversight of tobacco products and oppose efforts to limit FDA's authority as part of the FY 2019 Agriculture, Rural Development, and Food and Drug Administration and Related Agencies Appropriations Bill.
Coalition letter to U.S. House Appropriators to approve the authorized level of user fees for the FDA oversight of tobacco products and oppose efforts to limit FDA's authority as part of the FY 2019 Agriculture, Rural Development, and Food and Drug Administration and Related Agencies Appropriations Bill.
Coalition letter to U.S. House and Senate Conferees regarding H.R. 6147, urging the conferees to reject all tobacco riders that would weaken FDA oversight of tobacco products, including e-cigarettes and cigars.
FY 2019 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations (H.R. 6147); provisions related to Tobacco Policy Riders.
Coalition letter to leaders of the U.S. House Appropriations Committee requesting funding for the Agency for Healthcare Research and Quality (AHRQ) at a level equal to or higher than the House and Senate marks.
Coalition letter to leaders of the U.S. Senate Appropriations Committee requesting funding for the Agency for Healthcare Research and Quality (AHRQ) at a level equal to or higher than the House and Senate marks.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Joy |
Trimmer |
JD |
|
|
Amelia |
Suermann |
|
|
|
Maura |
Farrell |
|
|
|
Karl |
Melton |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TOR
16. Specific lobbying issues
H.R. 1215, the "Protecting Access to Care Act," all provisions.
H.R. 1704, the "Accessible Care by Curbing Excessive lawSuitS (ACCESS) Act," all provisions.
H.R. 1876, the "Good Samaritan Health Professionals Act of 2017," all provisions.
Comments urging floor action in regards to the Good Samaritan Health Professionals Act of 2018 (H.R. 1876).
Coalition letter to the Speaker of the House in support of the Good Samaritan Health Professionals Act of 2018 (H.R. 1876).
Coalition letter to leaders of the U.S. House Committee on Energy & Commerce requesting inclusion of H.R. 1876 in the Pandemic and All Hazards Preparedness Re-authorization Act of 2018 (S. 2852).
S. 2852, the Pandemic All Hazards Preparedness and Advancing Innovation Act of 2018; provisions related to malpractice/tort reform and H.R. 1876.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Joy |
Trimmer |
JD |
|
|
Amelia |
Suermann |
|
|
|
Maura |
Farrell |
|
|
|
Karl |
Melton |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
H.R. 1, the "Tax Cuts and Jobs Act of 2018," all provisions.
Letter to the Speaker of the U.S. House of Representatives and Minority Leader encouraging repeal of the Unrelated Business Income Tax (UBIT) on qualified transportation fringe benefits for tax-exempt organizations.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Joy |
Trimmer |
JD |
|
|
Amelia |
Suermann |
|
|
|
Maura |
Farrell |
|
|
|
Karl |
Melton |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TOB
16. Specific lobbying issues
Opposition to H.R. 564 and any appropriations riders that would exempt some cigars, including flavored cigars, from regulation under the Family Smoking Prevention and Tobacco Control Act (TCA).
Support for any legislation and/or regulation requiring all non-grandfathered private health insurance plans to cover preventative services given an "A" or "B" rating by the U.S. Preventative Services Taskforce (USPSTF), especially provisions relating to comprehensive benefits for tobacco cessation services.
Opposition to H.R. 1136, the "FDA Deeming Authority Clarification Act of 2017," all provisions.
Comments supporting the Food and Drug Administration's initiative to move toward a product standard to reduce the nicotine level in cigarettes to non-addictive or minimally addictive levels.
Coalition letter to U.S. Senate Appropriators to approve the authorized level of user fees for the FDA oversight of tobacco products and oppose efforts to limit FDA's authority as part of the FY 2019 Agriculture, Rural Development, and Food and Drug Administration and Related Agencies Appropriations Bill.
Coalition letter to leaders of the U.S. House Committee on Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies, urging allocation of funds for the Centers for Disease Control and Prevention's Office on Smoking and Health.
Coalition letter to leaders of the U.S. Senate Committee on Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies urging allocation of funds for the Centers for Disease Control and Prevention's Office on Smoking and Health.
Coalition letter to U.S. House and Senate Conferees regarding H.R. 6147, urging the conferees to reject all tobacco riders that would weaken FDA oversight of tobacco products, including e-cigarettes and cigars.
FY 2019 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations (H.R. 6147); provisions related to Tobacco Policy Riders.
Coalition letter to the Office of the U.S. Trade Representative (USTR) regarding tobacco provision in the U.S-Japan Free Trade Agreement with Japan, requesting that any agreement provide the protections necessary to enable both countries to adopt public health measures to protect their citizens from the death and disease caused by tobacco products without facing the risk of litigation by tobacco companies.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Food & Drug Administration (FDA), U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Joy |
Trimmer |
JD |
|
|
Amelia |
Suermann |
|
|
|
Maura |
Farrell |
|
|
|
Karl |
Melton |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code VET
16. Specific lobbying issues
Issues pertaining to scope of practice, in general.
Issues pertaining to professional standards for hearing instrument specialists.
17. House(s) of Congress and Federal agencies Check if None
Veterans Affairs - Dept of (VA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Amelia |
Suermann |
|
|
|
Joy |
Trimmer |
JD |
|
|
Maura |
Farrell |
|
|
|
Karl |
Melton |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Coalition letter to the Office of the U.S. Trade Representative (USTR) regarding tobacco provision in the U.S-Japan Free Trade Agreement with Japan, requesting that any agreement provide the protections necessary to enable both countries to adopt public health measures to protect their citizens from the death and disease caused by tobacco products without facing the risk of litigation by tobacco companies.
17. House(s) of Congress and Federal agencies Check if None
U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Joy |
Trimmer |
JD |
|
|
Amelia |
Suermann |
|
|
|
Maura |
Farrell |
|
|
|
Karl |
Melton |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
Issues related to in-office physician drug compounding, in general.
17. House(s) of Congress and Federal agencies Check if None
Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Joy |
Trimmer |
JD |
|
|
Amelia |
Suermann |
|
|
|
Maura |
Farrell |
|
|
|
Karl |
Melton |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |